Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or the Open Targets Genetics Portal which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.

Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.

Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Rapid publication

We are committed to rapid publication and making data, methods and results publicly available as soon as possible

Open collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data

Follow Us

Q&A with Babatomiwa Adebiyi, an intern with the Open Targets Platform

Helena Cornu | April 16, 2021

Babatomiwa Adebiyi is a computer science student at MIT. He tell us about his machine learning pr...

Job seeking during the pandemic: a Q&A with Kostas Tsirigos

Kostas Tsirigos | March 26, 2021

How do you prepare for a virtual interview? What is the remote onboarding process like? Open Targ...

Open Targets hosts Kiran Musunuru: insights into the genetic basis of coronary heart disease

Helena Cornu | March 16, 2021

An insight into Kiran Musunuru's career, from identifying mutations in ANGPTL3 that protect again...

Sharing is caring: why we need more freely available cancer GWAS summary statistics

Annalisa Buniello | March 11, 2021

Though progress has been made to integrate summary statistics into the GWAS Catalog, we make the ...

Getting a finer view on genes leading to Alzheimer’s disease risk

Helena Cornu | March 05, 2021

New research from Open Targets identifies new genetic regions associated with Alzheimer's disease...